United Therapeutics

(NASDAQ) UTHR

Current Price$570.97

Market Cap$24.55B

Since IPO (1999)+9,392%

5 Year+207%

1 Year+81%

1 Month+1%

United Therapeutics Financials at a Glance

Market Cap

$24.55B

Revenue (TTM)

$3.17B

Net Income (TTM)

$1.29B

EPS (TTM)

$27.09

P/E Ratio

21.35

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$570.97

Volume

16,641

Open

$577.40

Price

$570.97

Volume

16,641

Open

$577.40

Previous Close

$570.97

Daily Range

$570.19 - $580.38

52-Week Range

$272.12 - $609.35

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$570.97

Volume

16,641

Open

$577.40

Previous Close

$570.97

Daily Range

$570.19 - $580.38

52-Week Range

$272.12 - $609.35

UTHR News

A scientist looking through a microscope.

Page 1

UTHR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About United Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

1,400

CEO

Martine A. Rothblatt, PhD, MBA

Website

www.unither.com

Headquarters

Silver Spring, MD 20910, US

UTHR Financials

Key Financial Metrics (TTM)

Gross Margin

87%

Operating Margin

45%

Net Income Margin

41%

Return on Equity

20%

Return on Capital

24%

Return on Assets

19%

Earnings Yield

4.68%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.55B

Shares Outstanding

42.45M

Volume

16.64K

Avg. Volume

556.90K

Financials (TTM)

Gross Profit

$2.80B

Operating Income

$1.52B

EBITDA

$1.82B

Operating Cash Flow

$1.56B

Capital Expenditure

-$520.50M

Free Cash Flow

$1.04B

Cash & ST Invst.

$1.56B

Total Debt

$0.00

United Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$781.50M

-1.6%

Gross Profit

$648.10M

-7.7%

Gross Margin

82.93%

N/A

Market Cap

$24.55B

N/A

Market Cap/Employee

$18.81M

N/A

Employees

1,305

N/A

Net Income

$274.90M

-14.7%

EBITDA

$348.40M

-9.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$2.15B

-31.0%

Accounts Receivable

$312.00M

-3.1%

Inventory

$178.30M

+7.8%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

19.17%

N/A

Return on Invested Capital

23.50%

N/A

Free Cash Flow

$362.50M

-6.2%

Operating Cash Flow

$463.30M

+0.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RPRXRoyalty Pharma plc

RPRXRoyalty Pharma plc$53.97+0.20%

ILMNIllumina, Inc.

ILMNIllumina, Inc.$150.17+3.41%

WATWaters Corporation

WATWaters Corporation$342.18+1.05%

WSTWest Pharmaceutical Services, Inc.

WSTWest Pharmaceutical Services, Inc.$312.71-1.09%

DGXQuest Diagnostics Incorporated

DGXQuest Diagnostics Incorporated$193.99+0.58%

BIIBBiogen Inc.

BIIBBiogen Inc.$196.97+2.01%

INCYIncyte Corporation

INCYIncyte Corporation$97.34+0.25%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ASTCAstrotech

ASTCAstrotech$13.81+4.59%

NOKNokia

NOKNokia$15.68-0.05%

ONDSOndas

ONDSOndas$10.80+0.11%

FFord Motor Company

FFord Motor Company$15.88+0.04%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.92+0.01%

IRENIren

IRENIren$67.84+0.13%

TET1 Energy Inc.

TET1 Energy Inc.$10.96+0.05%

Questions About UTHR

What is the current price of United Therapeutics?

United Therapeutics is trading at $570.97 per share.

What is the 52-week range for United Therapeutics?

Over the past 52 weeks, United Therapeutics has traded between $272.12 and $609.35.

How much debt does United Therapeutics have?

As of the most recent reporting period, United Therapeutics reported total debt of $0.00.

How much cash does United Therapeutics have on hand?

United Therapeutics reported $1.07B in cash and cash equivalents in its most recent financial results.

What is United Therapeutics’s dividend yield?

United Therapeutics does not currently have a dividend yield.

United Therapeutics

United Therapeutics Financials at a Glance

UTHR News

Best Biotech ETFs to Buy in 2026

How to Invest in SPDR S&P Biotech ETF (XBI)

Earnings Summary on United Therapeutics

United Therapeutics Earnings Soared in Q1

Why United Therapeutics Blasted 14% Higher Today

This Pharma Can Breathe New Life Into Your Portfolio

How United Therapeutics Trounced Wall Street's Q3 Estimates

Here's Why United Therapeutics Fell 18.1% in May

UTHR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About United Therapeutics

UTHR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

United Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About UTHR

What is the current price of United Therapeutics?

What is the 52-week range for United Therapeutics?

How much debt does United Therapeutics have?

How much cash does United Therapeutics have on hand?

What is United Therapeutics’s dividend yield?

Premium Investing Services